Figure 2.

Risk of hospitalized VCD for each time period for the pooled studies (CYD14, CYD15, CYD23/57) over the 6-year period in participants seropositive by MI M0, NS1 M13 (Th9) and aged (A) ≥9 years, (B) <9 years. Study group classified as treated (participants included in the CYD-TDV group if they received at least 1 injection of CYD-TDV vaccine). n represents the number of subjects fulfilling the item listed; N represents the total number of subjects selected in subcohort. For all MI approaches n and N are average numbers from 10 iterations of multiple imputations. For NS1 M13 (Th9) participants with VCD cases before M13 were excluded from the analyses. Years 1 and 2 correspond to the active phase of the studies, and years 5 and 6 correspond to the surveillance expansion period. Abbreviations: CI, confidence interval; VCD, virologically confirmed dengue.